文献速递淋巴瘤

Polatuzumab vedotin联合化学免疫治疗(pola-R-CHP)一线治疗初治弥漫性大B细胞淋巴瘤在德国的成本-效果

Cost-effectiveness of polatuzumab vedotin in combination with chemoimmunotherapy (pola-R-CHP) in previously untreated diffuse large B-cell lymphoma in Germany.
PubMed 文献 · Br J Haematol · 2023-05-15

该研究采用Markov模型(终身 horizon)评估德国初治弥漫性大B细胞淋巴瘤(DLBCL)患者一线使用pola-R-CHP方案的成本-效果,进展率和生存数据从POLARIX试验外推。假设pola-R-CHP的5年无进展生存(PFS)率为69.6%、R-CHOP为62.6%,pola-R-CHP额外增加0.52生命年和0.65质量调整生命年(QALY),但增加31,988欧元成本,增量成本-效果比(ICER)为49,238欧元/QALY,在80,000欧元/QALY的支付意愿阈值下具有成本-效果。

要点

  • 在5年PFS率pola-R-CHP 69.6% vs R-CHOP 62.6%的假设下,pola-R-CHP增加0.52生命年和0.65 QALY。
  • pola-R-CHP增加成本31,988欧元,ICER为49,238欧元/QALY,低于80,000欧元/QALY的支付意愿阈值。
  • pola-R-CHP的成本-效果高度依赖于其长期结局和成本。

核心结论

  • 在假设的5年PFS率下,pola-R-CHP在80,000欧元/QALY的支付意愿阈值下具有成本-效果(ICER 49,238欧元/QALY)。
  • pola-R-CHP的成本-效果高度依赖于其长期结局和成本。

研究设计与样本

  • 采用Markov模型(终身horizon)评估德国初治DLBCL患者一线pola-R-CHP治疗的成本-效果。
  • 进展率和生存结局从POLARIX试验外推。

主要发现

  • 假设pola-R-CHP的5年PFS率为69.6%、R-CHOP为62.6%,pola-R-CHP额外增加0.52生命年和0.65 QALY,但增加31,988欧元成本。
  • 基于此,pola-R-CHP的ICER为49,238欧元/QALY,在80,000欧元/QALY的支付意愿阈值下具有成本-效果。

关键数值与推荐

  • 支付意愿阈值:80,000欧元/QALY。
  • 5年PFS率:pola-R-CHP 69.6% vs R-CHOP 62.6%。
  • 增量生命年:0.52;增量QALY:0.65;增量成本:31,988欧元;ICER:49,238欧元/QALY。

局限性

  • pola-R-CHP的长期结局目前未知。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We evaluated the cost-effectiveness of frontline polatuzumab vedotin-R-CHP (pola-R-CHP) treatment for patients with diffuse large B-cell lymphoma (DLBCL) in Germany by using a Markov model (lifetime horizon). Progression rates and survival outcomes were extrapolated from the POLARIX trial. Outcomes were measured in incremental cost-effectiveness ratios (ICERS) with a willingness-to-pay (WTP) threshold of €80 000/quality-adjusted life-years (QALY). Assuming, 69.6% 5-year PFS with pola-R-CHP and 62.6% 5-year PFS with R-CHOP, the addition of polatuzumab vedotin resulted in an additional 0.52 life-years and an incremental 0.65 QALYs but €31 988 additional cost. Based on this, pola-R-CHP was cost-effective (€49 238/QALY) at a WTP of €80 000/QALY. The cost-effectiveness of pola-R-CHP is highly dependent on its long-term outcomes and cost. Our analysis is limited by the fact that the long-term outcomes of pola-R-CHP are unknown at this time.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Kambhampati S, Shumilov E, Saumoy M, et al. Cost-effectiveness of polatuzumab vedotin in combination with chemoimmunotherapy (pola-R-CHP) in previously untreated diffuse large B-cell lymphoma in Germany. Br J Haematol. 2023. PMID: 37188351. doi:10.1111/bjh.18869

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。